Literature DB >> 19305959

[Differential hypertensive therapy according to the guidelines].

K H Rahn1.   

Abstract

The goal of antihypertensive therapy is to lower blood pressure and, by doing so, to decrease cardiovascular risk. Life style changes and drugs are available for the treatment of hypertensive patients. In order to reach the target blood pressure, most patients with hypertension need drug treatment in addition to life style changes. In all hypertensive patients, the target blood pressure is <140/90 mmHg. In patients with diabetes mellitus, with chronic renal failure as well as in patients with complications of hypertension and, thereby a very high cardiovascular risk, the target blood pressure is <130/80 mmHg. Diuretics, beta-blockers, calcium antagonists, ACE-inhibitors and angiotensin receptor blockers are the drugs of first choice in the treatment of hypertension. The selection among these drug classes has to consider probable side effects as well as accompanying diseases and complications of hypertension. One should also take into account that most of the beneficial effects of antihypertensive therapy is due to the decrease of blood pressure per se and that the majority of hypertensive patients require the combination of two or more antihypertensive drugs in order to reach the target blood pressure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305959     DOI: 10.1007/s00108-008-2292-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

1.  Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials.

Authors:  L A Magee; E Elran; S B Bull; A Logan; G Koren
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2000-01       Impact factor: 2.435

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

Authors:  Franz H Messerli; Giuseppe Mancia; C Richard Conti; Ann C Hewkin; Stuart Kupfer; Annette Champion; Rainer Kolloch; Athanase Benetos; Carl J Pepine
Journal:  Ann Intern Med       Date:  2006-06-20       Impact factor: 25.391

4.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Authors:  Eugene Braunwald; Michael J Domanski; Sarah E Fowler; Nancy L Geller; Bernard J Gersh; Judith Hsia; Marc A Pfeffer; Madeline M Rice; Yves D Rosenberg; Jean L Rouleau
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

5.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

6.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

7.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

8.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

Authors:  J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

9.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  3 in total

1.  Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists.

Authors:  Martin Thoenes; Ulrich Tebbe; Ludger Rosin; W Dieter Paar; Peter Bramlage; Wilhelm Kirch; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2011-01-05       Impact factor: 5.460

2.  Prevalence and determinants of controlled hypertension in a German population cohort.

Authors:  Neeltje van den Berg; Claudia Meinke-Franze; Thomas Fiss; Sebastian E Baumeister; Wolfgang Hoffmann
Journal:  BMC Public Health       Date:  2013-06-19       Impact factor: 3.295

3.  Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Authors:  Ina-Maria Rückert; Michaela Schunk; Rolf Holle; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-05-08       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.